Canada Approves Generic GLP-1s, Slashes Drug Costs

In a significant move for drug affordability, Canada has approved generic versions of semaglutide injections, commonly known as GLP-1 medications. These generics are expected to be available in pharmacies by early June, costing less than a third of their brand-name equivalents. This development is particularly impactful for Canadians who, like Elizabeth Doran, have faced substantial out-of-pocket expenses for weight loss and prediabetes management.

Doran, a retiree in Ottawa, Canada, had been paying between C$350 and C$500 monthly for Wegovy, as her prediabetes diagnosis did not qualify her for insurance coverage for diabetic seniors. The introduction of generics, however, has already prompted price reductions from Novo Nordisk and offers hope for patients like Esther Linetsky, who had to ration medication due to cost.

The Canadian approval follows similar actions in India, where generic GLP-1s have driven down prices. Experts suggest these Canadian generics could become an option for US patients, where brand-name GLP-1s can cost over US$1,000 monthly. However, due to differing patent laws, US access to generics is not anticipated until 2032, when the primary compound patent for semaglutide is set to expire. Novo Nordisk has stated that Canada's situation is unique to its patent timelines.